AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01918852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teysuno
Study NCT01918852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT01918852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT03763409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: active drug
Study NCT03763409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02088645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PP-F11N
Study NCT01040299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GangTrainer and tDCS
Description: The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
Study NCT01040299 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: control group1
Description: The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
Study NCT01040299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group2
Description: The control group 2 receive a total of 10 treatments with convectional physiotherapy.
Study NCT01099878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cycling Exercise with Functional Electrical Stimulation
Description: The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
Study NCT01099878 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cycling exercise
Description: The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
Study NCT01217723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
Study NCT01217723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
Description: The standard preparative regimen can be myeloablative or reduced intensity.
Study NCT00512473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: 0.9 % NaCl
Study NCT00512473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: 0.5 mg genotropin administered as a bolus at t = 0
Study NCT00512473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: 30 mg Somavert administered at t = - 36 hours
Study NCT03338829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive incentive
Description: Compensation is paid for each glucose test completed
Study NCT03338829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss aversion
Description: Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
Study NCT00799188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
Study NCT04352894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescence guided peritoneal exploration
Description: Intravenous injection of ICG
Study NCT03788941 — intervention group
Intervention type: PROCEDURE
Intervention: left atrial appendage closure and catheter ablation
Description: Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation.
Study NCT01291524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 400 to 500 calorie
Description: A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
Study NCT01291524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 600- 750 calorie
Description: A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
Study NCT01291524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, bedtime
Description: A single oral dose of 330 mg controlled release tablet administered at bedtime
Study NCT01291524 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered in the evening
Study NCT03630432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes.
Study NCT03630432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT00349219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
Study NCT00349219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
Study NCT03749330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CICU Team And Loved Ones Communicating (CICU TALC)
Description: When the necessary pre-intervention clinical encounters are completed, clinicians will go through the interprofessional team training to improve communication skills and teamwork in developing care plans and communicating with families in family meetings. The first step in the study is co-design of the intervention, so it will evolve as the study continues.
Study NCT02810457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKB238 (bevacizumab)
Study NCT02810457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin (bevacizumab)
Study NCT02810457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02810457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02810457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02810457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT04073537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study NCT04073537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Anlotinib blank analog capsule.
Study NCT04073537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.
Study NCT04073537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.
Study NCT04073537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Study NCT04073537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Study NCT01872312 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: treatment with valves (The Spiration® IBV Valve System)
Description: treat BPF
Study NCT02742662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable technology, smartscale
Study NCT02742662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone applications
Study NCT02742662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Weight Management Visits
Study NCT02742662 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Weight Management Visits
Study NCT01583140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness control
Description: Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
Study NCT01583140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
Study NCT00652054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Tablet
Study NCT03538314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 (300 microgram)
Study NCT03538314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF (37,5 or 75 microgram)
Study NCT03099382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
Study NCT02685163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidant ice-cream
Description: Narutal Antioxidant ice-cream
Study NCT02685163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Ice-cream
Description: Natural Control Ice-cream
Study NCT00499369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00499369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00499369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00499369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00499369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT03178474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®
Description: JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
Study NCT03178474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOFER Infant formula,TOFER®
Description: TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
Study NCT03178474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
Study NCT03665246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Mothers and Babies Course
Description: The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
Study NCT00090337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
Study NCT00090337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Patients undergo standard care
Study NCT02617446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV of matching saline solution
Study NCT02617446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
Study NCT01267968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 1500 mg (dosing detailed in Arm description)
Study NCT02924337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02924337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Study NCT02924337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT02650609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT02650609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01994395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Stride Management Assist (SMA) System
Description: Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
Study NCT00556166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy Gastric Stimulator
Description: The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control.
Study NCT03286595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobi mHealth app
Description: Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment.
Study NCT01994395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impairment based therapy
Description: Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
Study NCT01548690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine Phenylacetate
Description: Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4).
Study NCT01626976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Solution, doses range from 20 to 200 mg, single dose
Study NCT02641730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
Study NCT02641730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
Study NCT01350609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine/Candesartan (BAY 98-7106)
Description: Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
Study NCT01350609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)
Description: Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
Study NCT02601326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral mesh Rectopexy
Description: Laparoscopic fixation of rectum to sacral promontory using mesh
Study NCT02601326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delorme's procedure
Description: Transanal excision of rectal mucosa and plication of muscle layer
Study NCT04625634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 days of work heat stress
Description: 2 consecutive days of identical simulated structural firefighting tasks.
Study NCT03054168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustanon 250
Description: The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
Study NCT03054168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
Study NCT03054168 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05209139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
Study NCT05209139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
Study NCT05209139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice placebo
Description: One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
Study NCT03307252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral solution